Barclays
MGX icon

Barclays’s Metagenomi Therapeutics MGX Stock Holding History

Barclays’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199 Buy
+167
New +$223 ﹤0.01% 5110
2026
Q1 		– Sell
-3
Closed -$5 – 5518
2025
Q4 		$5 Hold
3
– – ﹤0.01% 5167
2025
Q3 		$7 Hold
3
– – ﹤0.01% 5411
2025
Q2 		$4 Sell
3
-28,845
-100% -$45.2K ﹤0.01% 5175
2025
Q1 		$39.2K Sell
28,848
-13,633
-32% -$32.5K ﹤0.01% 4673
2024
Q4 		$153K Buy
42,481
+33,783
+388% +$81.5K ﹤0.01% 4421
2024
Q3 		$18.9K Buy
8,698
+6,532
+302% +$22.7K ﹤0.01% 4901
2024
Q2 		$8.84K Buy
+2,166
New +$14.9K ﹤0.01% 4530

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's MGX Position: Q2 2026 in Review

Barclays opened a new position in Metagenomi Therapeutics (MGX) in Q2 2026: 167 shares worth $199. The stake represents ﹤0.01% of the portfolio and ranks #5110 among its holdings. This is a return to the name: Barclays previously reported a position in MGX as recently as Q4 2025.

Barclays first reported a position in MGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $153K in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Barclays held 167 shares of Metagenomi Therapeutics worth $199 as of Q2 2026.
  • Metagenomi Therapeutics was a new Barclays position in Q2 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5110 holding.
  • Barclays first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Metagenomi Therapeutics position peaked at $153K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.